DENDREON PHARMACEUTICALS, LLC

Lobbying for DENDREON PHARMACEUTICALS, LLC

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · California · House · Senate · $59,650.00 expenses · posted Dec 2, 2025

Lobbying activity 1

Medical/Disease Research/Clinical Labs

Access to autologous cellular immunotherapies in Medicare Part B. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.